Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Lawson Health Research Institute |
---|---|
Information provided by: | Lawson Health Research Institute |
ClinicalTrials.gov Identifier: | NCT00480168 |
The purpose of this study is to observe patients aged 6-18 with various psychiatric diagnosis being treated with drugs called atypical antipsychotics to determine the effects of the drugs on growth, weight gain, and laboratory tests.
Condition | Intervention |
---|---|
Adverse Effects |
Drug: Atypical antipsychotics |
Study Type: | Observational |
Study Design: | Natural History, Longitudinal, Defined Population, Prospective Study |
Official Title: | A Prospective Study to Assess Metabolic Changes in Children and Adolescents Aged 6-18 Treated With Atypical Antipsychotics |
Estimated Enrollment: | 50 |
Study Start Date: | May 2007 |
Estimated Study Completion Date: | May 2007 |
Introduction: Antipsychotics have been used for many years to treat serious mental illnesses like schizophrenia and bipolar illness (manic depression). These older drugs carry a higher risk of side effects like shaking, stiffness, restlessness or uncontrolled movements. They may occur when the drugs are first taken, or later, after years of use. Newer drugs called atypical antipsychotics (ATA's) are much less likely to cause these problems. Their lack of these side effects and greater safety have led doctors to use them for other diseases in both adults and younger patients. They have proved to be helpful in aggression, impulsiveness, anxiety and mood swings. Unfortunately, a number of other side effects, such as weight gain, increased rates of diabetes and increases in cholesterol have also been identified. While a lot of current research into these side effects has been done in adults, there have been few studies with younger patients. The research so far has been brief and involved small numbers. This is especially important in this young and potentially vulnerable group of patients.
Study Methods: This research will study children and teens aged 6 to 18 who are being treated with the newer drugs for the first time. If agreeable to the patients and their parents or guardians, their doctors will prescribe one of the newer drugs and will measure the effects, if any, on weight, blood sugar, cholesterol as well as the improvement in their condition. Weight, height, and blood work will be done before the drug is started, and 6 and 12 months after they have been on it, comparing the results with their original values. The doctor, the patient and the parent or guardian will rate the patients' condition at these times, as well, to evaluate their improvement.
Ages Eligible for Study: | 6 Years to 18 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Tamison M Doey, MD FRCPC | 519 258 0484 ext 138 | drtamison@yahoo.com |
Contact: Brenda Davidson | 519 685 8500 ext 77130 | brenda.davidson@lhsc.on.ca |
Canada, Ontario | |
London Health Sciences Centre | |
London, Ontario, Canada, N6A 4G5 | |
Windsor Regional Hospital | |
Windsor, Ontario, Canada, N8W 1L9 |
Principal Investigator: | Tamison M Doey, MD FRCPC | University of Western Ontario, Canada |
Study ID Numbers: | 11172 |
Study First Received: | May 25, 2007 |
Last Updated: | May 25, 2007 |
ClinicalTrials.gov Identifier: | NCT00480168 |
Health Authority: | Canada: Health Canada |
child adolescent weight gain endocrine disruptors |
Body Weight Weight Gain |